Peter Kamenický
About
In The Last Decade
Peter Kamenický
97 papers receiving 3.0k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Endocrinology, Diabetes and Metabolism 1.5k
- Nephrology 1.1k
- Surgery 830
- Genetics 515
- Molecular Biology 499
Countries citing papers authored by Peter Kamenický
This map shows the geographic impact of Peter Kamenický's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kamenický with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kamenický more than expected).
Fields of papers citing papers by Peter Kamenický
This network shows the impact of papers produced by Peter Kamenický. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kamenický. The network helps show where Peter Kamenický may publish in the future.
Co-authorship network of co-authors of Peter Kamenický
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Kamenický. A scholar is included among the top collaborators of Peter Kamenický based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Kamenický. Peter Kamenický is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 0 | |
| 6 | 1 | |
| 7 | 9 | |
| 8 | 6 | |
| 9 | 3 | |
| 10 | 0 | |
| 11 | 6 | |
| 12 | 3 | |
| 13 | 4 | |
| 14 | 2 | |
| 15 | 18 | |
| 16 | Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia breakdown → | 316 |
| 17 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF BUROSUMAB, AN ANTI-FGF23 ANTIBODY, IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH) | 1 |
| 18 | 230 | |
| 19 | 47 | |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.